vs

Side-by-side financial comparison of HIGHWOODS PROPERTIES, INC. (HIW) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $203.4M, roughly 1.0× HIGHWOODS PROPERTIES, INC.). HIGHWOODS PROPERTIES, INC. runs the higher net margin — 14.6% vs -62.0%, a 76.6% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -1.1%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -1.9%).

Highwoods Properties, Inc. is a publicly traded real estate investment trust that owns, develops, acquires, and manages high-quality office properties primarily located in fast-growing metropolitan areas across the Southeastern and Mid-Atlantic regions of the United States. Its client base includes corporate tenants across diverse industry segments such as technology, healthcare, finance, and professional services.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

HIW vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.0× larger
RARE
$207.3M
$203.4M
HIW
Growing faster (revenue YoY)
RARE
RARE
+26.9% gap
RARE
25.9%
-1.1%
HIW
Higher net margin
HIW
HIW
76.6% more per $
HIW
14.6%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-1.9%
HIW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HIW
HIW
RARE
RARE
Revenue
$203.4M
$207.3M
Net Profit
$29.7M
$-128.6M
Gross Margin
Operating Margin
67.2%
-54.7%
Net Margin
14.6%
-62.0%
Revenue YoY
-1.1%
25.9%
Net Profit YoY
1029.4%
3.5%
EPS (diluted)
$0.25
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIW
HIW
RARE
RARE
Q4 25
$203.4M
$207.3M
Q3 25
$201.8M
$159.9M
Q2 25
$200.6M
$166.5M
Q1 25
$200.4M
$139.3M
Q4 24
$205.5M
$164.6M
Q3 24
$204.3M
$139.5M
Q2 24
$204.7M
$147.0M
Q1 24
$211.3M
$108.8M
Net Profit
HIW
HIW
RARE
RARE
Q4 25
$29.7M
$-128.6M
Q3 25
$13.7M
$-180.4M
Q2 25
$19.2M
$-115.0M
Q1 25
$100.0M
$-151.1M
Q4 24
$-3.2M
$-133.2M
Q3 24
$15.5M
$-133.5M
Q2 24
$64.8M
$-131.6M
Q1 24
$27.2M
$-170.7M
Operating Margin
HIW
HIW
RARE
RARE
Q4 25
67.2%
-54.7%
Q3 25
67.3%
-106.9%
Q2 25
68.3%
-64.8%
Q1 25
67.5%
-102.6%
Q4 24
65.2%
-74.3%
Q3 24
67.8%
-94.6%
Q2 24
68.5%
-79.1%
Q1 24
66.7%
-151.9%
Net Margin
HIW
HIW
RARE
RARE
Q4 25
14.6%
-62.0%
Q3 25
6.8%
-112.8%
Q2 25
9.6%
-69.0%
Q1 25
49.9%
-108.5%
Q4 24
-1.6%
-80.9%
Q3 24
7.6%
-95.7%
Q2 24
31.6%
-89.5%
Q1 24
12.9%
-156.8%
EPS (diluted)
HIW
HIW
RARE
RARE
Q4 25
$0.25
$-1.28
Q3 25
$0.12
$-1.81
Q2 25
$0.17
$-1.17
Q1 25
$0.91
$-1.57
Q4 24
$-0.04
$-1.34
Q3 24
$0.14
$-1.40
Q2 24
$0.59
$-1.52
Q1 24
$0.25
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIW
HIW
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$27.4M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.4B
$-80.0M
Total Assets
$6.3B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIW
HIW
RARE
RARE
Q4 25
$27.4M
$421.0M
Q3 25
$26.3M
$202.5M
Q2 25
$21.2M
$176.3M
Q1 25
$20.1M
$127.1M
Q4 24
$22.4M
$174.0M
Q3 24
$23.6M
$150.6M
Q2 24
$27.0M
$480.7M
Q1 24
$16.4M
$112.3M
Stockholders' Equity
HIW
HIW
RARE
RARE
Q4 25
$2.4B
$-80.0M
Q3 25
$2.4B
$9.2M
Q2 25
$2.4B
$151.3M
Q1 25
$2.4B
$144.2M
Q4 24
$2.4B
$255.0M
Q3 24
$2.4B
$346.8M
Q2 24
$2.4B
$432.4M
Q1 24
$2.4B
$140.3M
Total Assets
HIW
HIW
RARE
RARE
Q4 25
$6.3B
$1.5B
Q3 25
$6.1B
$1.2B
Q2 25
$6.1B
$1.3B
Q1 25
$6.1B
$1.3B
Q4 24
$6.0B
$1.5B
Q3 24
$6.0B
$1.5B
Q2 24
$6.0B
$1.6B
Q1 24
$6.0B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIW
HIW
RARE
RARE
Operating Cash FlowLast quarter
$359.2M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
12.09×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIW
HIW
RARE
RARE
Q4 25
$359.2M
$-99.8M
Q3 25
$96.7M
$-91.4M
Q2 25
$116.5M
$-108.3M
Q1 25
$46.3M
$-166.5M
Q4 24
$403.6M
$-79.3M
Q3 24
$97.5M
$-67.0M
Q2 24
$130.0M
$-77.0M
Q1 24
$72.4M
$-190.7M
Free Cash Flow
HIW
HIW
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
HIW
HIW
RARE
RARE
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
HIW
HIW
RARE
RARE
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Q1 24
3.0%
Cash Conversion
HIW
HIW
RARE
RARE
Q4 25
12.09×
Q3 25
7.05×
Q2 25
6.06×
Q1 25
0.46×
Q4 24
Q3 24
6.30×
Q2 24
2.01×
Q1 24
2.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HIW
HIW

Raleigh NC$45.6M22%
Nashville TN$38.7M19%
Atlanta GA$36.1M18%
Charlotte NC$26.1M13%
Tampa FL$22.2M11%
Orlando FL$14.4M7%
Other$11.4M6%
Richmond VA$8.8M4%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons